Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod in Chronic GVHD
NCT06244628Phase 2Recruiting
- Sponsor
- Xuzhou Medical University
- Start
- Jan 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iguratimod in chronic graft-versus-host disease (cGVHD), sponsored by Xuzhou Medical University. Started Jan 2024; status: recruiting.
02
Drugs
iguratimod
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06244628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06244628.